dinadax sapiens (2017.) cits, košļājamā nūjiņa
opko health spain, s.l.u. - cits, košļājamā nūjiņa
human albumin csl behring 200 g/l šķīdums infūzijām
csl behring gmbh, germany - albumīns, cilvēka - Šķīdums infūzijām - 200 g/l
cosentyx
novartis europharm limited - sekukinumabs - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imūnsupresanti - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriātisko arthritiscosentyx, atsevišķi vai kombinācijā ar metotreksātu (mtx), ir indicēts, lai ārstētu aktīvo psoriātiskā artrīta ārstēšanai pieaugušiem pacientiem, ja atbilde uz iepriekšējo slimību modificējošiem anti reimatisko narkotiku (dmard) terapija ir bijusi nepietiekama. aksiālie spondyloarthritis (axspa), ankilozējošais spondilīts (as, radiogrāfisko aksiālie spondyloarthritis)cosentyx ir indicēts, lai ārstētu aktīvo ankilozējošā spondilīta pieaugušajiem, kuri atbildēja nepareizi uz parasto terapiju. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
osteogēls 10% gels
silvanols, sia, latvia - dimetilsulfoksīds - gels - 10%
canidryl 50 mg
chanelle pharmaceuticals manufacturing limited, Īrija - karprofēns - tabletes - 50 mg - suņi
ovulike
t.p.whelehan son&co. ltd., Īrija - buserelīna acetāts - šķīdums injekcijām - 0,004 mg/ml - liellopi; truši; zirgi
oestrophan 0.25 mg/ml šķīdums injekcijām
bioveta, a.s., Čehija - cloprostenol - šķīdums injekcijām - 0.25 mg/ml - govis; sivēnmātes; ķēves
ironlink kids 10 mg (2020.) šķidrums
pharmalink s.l. - šķidrums
ironlink 14 mg (2020.) šķidrums
pharmalink s.l. - šķidrums
dinadax energy zero (2022.) cits, košļājamās nūjiņas
cits, košļājamās nūjiņas